Supplemental Tables and Figures

Reliability and validity of a Spanish-language measure assessing clinical capacity to sustain Pediatric Early Warning Systems (PEWS) in resource-limited hospitals

Table of Contents:

Content	Page
Supplemental Table 1: Participating center relevant characteristics and	2
response rates	2
Supplemental Figure 1: English version of the final survey instrument	4
Supplemental Figure 2: Sample CSAT Report	8
Supplemental Figure 3: Focus group facilitator guide	10
Supplemental Table 2: Focus group code book	13
Supplemental Table 3: CSAT domains and time from PEWS implementation	14
Supplemental Table 4: Center demographics influencing CSAT results	4.5
(among centers)	15
Supplemental Figure 4: CSAT result trends with time from PEWS	1.0
implementation (Center-level, n=29)	16
Supplemental Figure 5: CSAT result trends with time from PEWS	17
implementation (Individual-level, n=169)	17
Supplemental Table 5: Focus group participant demographics	18

Supplemental material

Center	Country	Type of Hospital	Hospital Funding Structure	New Annual Cancer Diagnoses	Pediatric Oncology Unit Structure	Time since Implementation of PEWS (months)	Number of Staff Working in Center	Staff Surveyed	Responses	Response Rate (%)
1	Argentina	General (Adult and Peds)	Mix (Public/private partnership)	37	Separate pediatric	2.10	85	15	13	87%
2	Brazil	Pediatric Multidisciplinary	Public	140	Integrated with pediatrics	1.10	71	10	8	80%
3	Chile	Pediatric Multidisciplinary	Public	100	Separate pediatric	39.67	70	8	6	75%
4	Costa Rica	Pediatric Multidisciplinary	Public	168	Separate pediatric	6.13	49	5	3	60%
5	Dominican Republic	Pediatric Multidisciplinary	Public	99	Separate pediatric	19.33	35	7	7	100%
6	Dominican Republic	Pediatric Multidisciplinary	Public	59	Separate pediatric	22.40	48	9	6	67%
7	Ecuador	Oncology (Adult and Peds)	Mix (Public/private partnership)	94	Separate pediatric	24.43	40	6	5	83%
8	Ecuador	Oncology (Adult and Peds)	Mix (Public/private partnership)	75	Separate pediatric	12.27	48	6	6	100%
9	El Salvador	Pediatric Multidisciplinary	Public	185	Separate pediatric	22.40	42	4	4	100%
10	Guatemala	Pediatric Oncology	Mix (Public/private partnership)	513	Separate pediatric	69.07	250	6	6	100%
11	Haiti	Pediatric Multidisciplinary	Private	89	Separate pediatric	22.40	16	4	3	75%
12	Honduras	General (Adult and Peds)	Public	365	Integrated with pediatrics	38.63	35	5	5	100%
13	Mexico	General (Adult and Peds)	Public	19	Separate pediatric	19.33	49	4	4	100%
14	Mexico	Oncology (Adult and Peds)	Public	110	Separate pediatric	9.20	77	6	5	83%
15	Mexico	Oncology (Adult and Peds)	Mix (Public/private partnership)	27	Integrated with pediatrics	22.80	19	4	1	25%
16	Mexico	Pediatric Multidisciplinary	Public	143	Separate pediatric	7.17	55	6	6	100%

17	Mexico	General (Adult and Peds)	Public	42	Integrated with pediatrics	15.33	230	7	5	71%
18	Mexico	General (Adult and Peds)	Public	136	Separate pediatric	6.13	103	6	5	83%
19	Mexico	General (Adult and Peds)	Public	58	Separate pediatric	7.17	66	9	4	44%
20	Mexico	General (Adult and Peds)	Public	45	Separate pediatric	10.23	31	4	4	100%
21	Mexico	General (Adult and Peds)	Public	60	Separate pediatric	26.47	34	6	5	83%
22	Mexico	Pediatric Oncology	Private	60	Separate pediatric	51.83	103	9	9	100%
23	Mexico	Pediatric Multidisciplinary	Public	121	Separate pediatric	13.30	94	6	4	67%
24	Mexico	Pediatric Multidisciplinary	Public	49	Separate pediatric	21.37	227	5	4	80%
25	Nicaragua	Pediatric Multidisciplinary	Public	301	Separate pediatric	14.30	39	5	3	60%
26	Panama	Pediatric Multidisciplinary	Public	55	Separate pediatric	20.37	22	10	7	70%
27	Peru	General (Adult and Peds)	Mix (Public/private partnership)	200	Separate pediatric	5.17	22	13	9	69%
28	Peru	General (Adult and Peds)	Public	150	Separate pediatric	7.17	42	12	10	83%
29	Peru	Oncology (Adult and Peds)	Public	800	Separate pediatric	17.37	230	13	12	92%
TOTAL								210	169	80%

Supplemental Figure 1: English version of the Clinical Sustainability Assessment Tool (CSAT) final survey instrument

CSAT Questions

In the following questions, rate the EVAT program across a range of specific factors that affect sustainability. Please respond to as many items as possible. The more honest you can be with your answers, the more helpful the report will be in moving forward with your program's sustainability planning. If you truly feel you are not able to answer an item, you may select "NA."

For each statement, select the number that best indicates the extent to which you agree. The scale has a range from 1 to 5. Selecting 1 indicates "strongly disagree" and selecting 5 indicates "strongly agree."

NA	1	2	3	4	5
Not able to	Strongly	Disagree	Neither Disagree	Agree	Strongly
answer	Disagree		nor Agree		Agree

Engaged Staff & Leadership: Having supportive frontline staff and management within the organization

- 1. EVAT engages leadership and staff throughout the process.
- 2. Clinical champions of EVAT are recognized and respected.
- 3. EVAT has engaged, ongoing champions.
- 4. EVAT has a leadership team made of multiprofessional partnerships.
- 5. EVAT has team-based collaboration and infrastructure.

Engaged Stakeholders: Having external support and engagement for EVAT

Stakeholders: individuals, groups, or organizations that positively or negatively influence the results of a project/initiative, which has authority and power.

- 1. EVAT engages the patient and family members as stakeholders.
- 2. There is respect for all stakeholders involved in EVAT.
- 3. The EVAT importance is valued by a diverse set of stakeholders.
- 4. EVAT engages other medical teams and community partnerships as appropriate.
- 5. The EVAT leadership team has the ability to respond to stakeholder feedback about EVAT.

Organizational Readiness: Having the internal support and resources needed to effectively manage EVAT

- 1. Organizational systems are in place to support the various needs of EVAT.
- 2. EVAT fits in well with the culture of the team.
- 3. EVAT has feasible and sufficient resources (e.g., time, space, funding) to achieve its goals.
- 4. EVAT has adequate staff to achieve its goals.
- 5. EVAT is well integrated into the operations of the hospital.

Workflow Integration: Designing EVAT to fit into existing practices and technologies

- 1. EVAT is built into the clinical workflow.
- 2. EVAT is easy for clinicians to use.
- 3. EVAT integrates well with established clinical practices.
- 4. EVAT aligns well with other clinical systems (e.g., EMR).
- 5. EVAT is designed to be used consistently.

Implementation & Training: Using processes that guide the direction, goals, and strategies of EVAT

- 1. EVAT clearly outlines roles and responsibilities for all staff.
- 2. The reason for EVAT is clearly communicated to and understood by all staff.
- 3. Staff receive ongoing coaching, feedback, and training.
- 4. EVAT implementation is guided by feedback from stakeholders.
- 5. EVAT has ongoing education across professions.

Monitoring & Evaluation: Assessing EVAT to inform planning and document results

- 1. EVAT has measurable process components, outcomes, and metrics.
- 2. Evaluation and monitoring of EVAT are reviewed on a consistent basis.
- 3. EVAT has clear documentation to guide process and outcome evaluation.
- 4. EVAT monitoring, evaluation, and outcomes data are routinely reported to the clinical care team.
- 5. EVAT process components, outcomes, and metrics are easily assessed and audited.

Outcomes & Effectiveness: Understanding and measuring EVAT outcomes and impact

- 1. EVAT has evidence of beneficial outcomes.
- 2. EVAT is associated with improvement in patient outcomes that are clinically meaningful.
- 3. EVAT is clearly linked to positive health or clinical outcomes.
- 4. EVAT is cost-effective.
- 5. EVAT has clear advantages over alternatives (including not implementing EVAT)

Intervention

The following questions will ask about EVAT. Please answer considering the time BEFORE COVID at your institution.

- 6. Please rate the strength of the scientific evidence supporting EVAT implementation.
 - a. Very weak
 - b. Weak
 - c. Neither weak nor strong
 - d. Strong
 - e. Very strong
 - f. Don't know/NA
- 7. How important is EVAT to provide quality care to your patients?
 - a. Not at all important
 - b. Somewhat unimportant
 - c. Neither important nor unimportant
 - d. Somewhat important
 - e. Very important
- 8. How difficult was the implementation of EVAT, or do you expect the implementation of EVAT to be, in your hospital?
 - a. Very difficult
 - b. Somewhat difficult
 - c. Neither easy nor difficult
 - d. Somewhat easy
 - e. Very easy
 - f. Don't know/NA

5

- 9. Regarding patients under my care, how often is EVAT used in their care?
 - a. EVAT is not yet implemented in my hospital
 - b. None of the time
 - c. Some of the time
 - d. Most of the time
 - e. All of the time

Organization

Please indicate how much you agree or disagree with each of the following statements.

		Not aplicable	Strongly Disagree	Somewhat Disagree	Neither agree nor disagree	Somewhat agree	Strongly Agree
	Our resources (personnel, time, financial) are too tightly limited to improve care quality.		1	2	3	4	5
11.	Our EVAT implementation team understands and uses quality improvement skills effectively.		1	2	3	4	5
12.	Our clinical team has changed or created systems in the hospital that make it easier to provide high quality care.		1	2	3	4	5
13.	We choose new processes of care that are more advantageous than the old to everyone involved (patients, clinicians, and our entire clinical team).		1	2	ω	4	5
14.	The working environment in our clinical team is collaborative and cohesive, with shared sense of purpose, cooperation, and willingness to contribute to the common good.		1	2	3	4	5
15.	Our clinical team has greatly improved quality of care in the past 12 months.		1	2	3	4	5

Participant

The following questions will ask about your work. Please indicate your response for each question or statement.

- 16. What is your primary profession?
 - a. Nurse
 - b. Physician
 - c. Healthcare Administration
 - d. Other (please list):

Where is your primary area of work	17.	Where	is your	primary	area of	work?
------------------------------------------------------	-----	-------	---------	---------	---------	-------

- e. Pediatric or Pediatric Hematology-Oncology floor
- f. Intensive Care Unit
- g. Non-clinical work
- h. Other (please list):
- 18. In relation to EVAT, what is your primary role in the implementation team?
 - a. EVAT leader
 - b. Clinical staff
 - c. Hospital administrator
 - d. Data manager (responsible to collect/send EVAT data)
 - e. Other ______
- 19. How many years have you worked since completing medical or nursing training?
 - a. 0-5 years
 - b. 6-10 years
 - c. 11-15 years
 - d. 16-20 years
 - e. Greater than 20 years
 - f. N/A
- 20. How many years have you worked at this hospital?
 - g. 0-5 years
 - h. 6-10 years
 - i. 11-15 years
 - j. 16-20 years
 - k. Greater than 20 years
- 21. What is your gender?
 - a. Male
 - b. Female
 - c. Other
- 22. What is your age?
 - a. <30 years old
 - b. 30-40
 - c. 40-50
 - d. >50 years old

Supplemental Figure 2: Sample CSAT Report



EVAT Sustainability Report

Date: Aug 05, 2020

Overall Sustainability Score:


4.4

- The Clinical Sustainability Assessment Tool (CSAT) allows stakeholders to rate a practice on the extent to which it is supported by processes and structures that will increase the likelihood of sustainability.
- Assessment results can be used to identify next steps in building capacity for sustainability in order to position efforts for long-term success.

Interpreting the Results

- The average rating for each sustainability domain is based on the responses provided by 169 of the 211 people invited to participate.
- There is no minimum rating that guarantees sustainability of a clinical practice. However, lower rating does indicate opportunities for improvement that you may want to focus on when developing a plan for sustainability.
- These results are a snapshot of a clinical practice's sustainability capacity, and we recommend taking the assessment again after 6 months or a year.

Average Sustainability by Domain



Below you will find the highest components we recommend maintaining (strengths) and the components in which you must focus (opportunities).

Strengths

Opportunities

EVAT has evidence of beneficial outcomes. (Outcomes & Effectiveness)

Space, funding) to achieve its goals. (Organizational Readiness)

EVAT is associated with significant improvement in clinical patient outcomes. (Outcomes & Effectiveness)

ol Organizational systems are in place to support the various needs of EVAT. (Organizational Readiness)

4.8 EVAT is clearly linked to positive health or clinical outcomes. (Outcomes & Effectiveness)

EVAT engages other medical teams and community partnerships as appropriate. (Engaged Stakeholders)

4.8

EVAT is cost-effective. (Outcomes & Effectiveness)

8



Supplemental Figure 3: Focus group facilitator guide

	AND THE STATE OF T
	Welcome to this focus group that aims to discuss the EVAT Sustainability Report
	based on the Clinical Sustainability Assessment Tool (CSAT), that you received. Thank
	you again for accepting our invitation and for giving us some of your valuable time to
+	chat with us.
•	This session is part of a series of focus groups that we will be conducting with people
	who completed the Clinical Sustainability Assessment Tool (CSAT) in different
	institutions and countries. Our goal today is to ensure that everyone has the
	opportunity to share their comments and feedback with the group in order to
	evaluate and improve the CSAT assessment tool.
	Make sure you have the EVAT Sustainability Report (based on the CSAT) that was
Description of rules to	provided to you.
follow: Before we begin,	This session will be recorded, which will allow me to focus my attention on you
I would like to go over	rather than trying to take notes about the conversation.
	• It is important that only one person speaks at a time in order to facilitate later
follow during this focus	transcription of the recording.
_	The audio obtained from the recording will be transcribed and de-identified for
group.	later analysis. We will not use video for the purposes of this analysis.
	For the purposes of this session, we will identify ourselves and refer to each
	participant using only their first names to avoid hierarchies and facilitate
	communication. We remind you that your comments will be subsequently de-
	identified.
	What is shared in the session stays in the session. As facilitators, we are
	committed to maintaining the confidentiality of what is discussed here and, in
	the same way, we appreciate that what is said here is not discussed with other
	people once the session is over.
	There are no right or wrong answers to the questions we will ask today, we just
	want to know about your ideas, experiences and opinions, all of which are of
	great value to us. Listening to each other's points of view is imperative, both
	positive and negative. It is important for us to listen to everyone's ideas and
	opinions. We want the ideas of each participant in the focus group to be equally
	represented; so, do not hesitate to share your opinions.
	You do not have to agree with others, but you must listen to and respect the
	opinions expressed by other participants.
	You do not have to wait to be called to intervene in the question round. It is an
	open discussion so you can comment at any time.
Technical	We appreciate that each participant keeps their camera active throughout the
considerations:	session. If you have any problem activating your camera, remember that you can
considerations.	ask (co-facilitator) for help via chat.
	It is recommended to use the grid view so you can see all the participants on one
	screen. This will help give the feel of an in-person meeting. The grid view can be
	selected from the menu in the upper right corner of your screen.
	Remember to keep your microphone muted, and to activate it whenever you
	want to comment or say something.
	 We understand that you may need to answer a phone call or a pager message. If
	you can turn off those devices, please do so. If that is not possible, please mute
	your microphone while you are on the call and return to the group as soon as
	possible.
	o Please use the "chat" function only to communicate technical problems as we want you to express your comments out loud on the subject at hand today.
	want you to express your comments out loud on the subject at hand today.

Doubts before	Do you have any questions regarding the rules or a technical matter before we start
proceeding	the question round?
Introduction of the	Now we will introduce ourselves, briefly and in turns. In this section I will call you so
facilitators and	that each one of you can tell what your name is, your place of origin, your role as part
participants:	of your work team and how many months or years of experience each one has
post orospositor	providing medical care to children with cancer.
	(The facilitator will lead this part of the session using the list of participants).
	My name is <state and="" length="" name,="" of="" origin,="" role,="" service="" your="">, and I will serve as a</state>
	facilitator for our conversation today
	[if a co-facilitator is present]
	Today we are joined by <name co-facilitator="" of="" the=""> who will serve as co-facilitator,</name>
	take notes, and help us to ensure that everything runs smoothly from a technical
	standpoint. <co- facilitator=""> will be waiting for your comments in the chat to attend</co->
	to any technical problem (audio, difficulties to see the video, etc.) Remember to keep
	your camera turned on as much as possible.
	Introduction of the participants:
	Now the moderator will call each participant to introduce themselves. (The facilitator will lead this part of the session using the list of participants)
Introduction to	In the previous section I have called you to introduce yourself. However, I would like
	to clarify that in the question section you do not have to wait to be called. Please give
Question Round:	your opinion or comment when you consider it appropriate.
Understandability and	1. Do you feel that the score is easy to understand?
utility of the report:	a. What does the score mean to you? How do you interpret the score?
The CSAT Sustainability	b. Can you tell what are the strengths and weakness of your center based on the
Report provides you with a	report? (Pause after the question to await additional comments. Follow new
score to help you	routes according to comments and opinions)
understand how prepared	c. Is there anything in the report that surprised you? Or something that you disagree with?
your hospital is to	2. How does the written information in the report help you understand how to use
maintain EVAT.	your score?
	3. If you were able, do you feel like you could take action to improve sustainability of
	[name of intervention] based on this report? How? Please give an example based
	on your report. (Keep the focus more on the report, rather than EVAT)
	4. What other information you would need that would help you take action based on
	this report?
	5. Do you find the second page useful? Informative?
Overall look and feel:	1. In your opinion, does the way in which the information is organized make sense?
We're also interested in	a. What would you do to improve it?
your opinion about the	b. Is there something missing from the report?
best way to present the	c. Does the report appear to you to be coherently organized?
information in the report	2. Is there any aspects of the report that you find confusing? Or that you would
so that people would like	recommend changing? (tell them: there might be something we would like to
to read it. We've broken it	change that we think would make it easier to read or understand or just aesthetics)
up into these sections:	What would you suggest? For example,
- score	a. Score review box?
- written text	b. Written text? (ask them: Do you think it has a lot of text? Or if they could
- domain graphs, and	communicate the same idea with fewer words, or perhaps explain more specifically offering more details or more descriptive? Maybe make the report a
- details on the 2 nd page	, , , , , , , , , , , , , , , , , , , ,
(Request that the co-	little more concise?) c. The domain averages graph?
facilitator share his/her	d. Detailed info on 2 nd page?
	u. Detailed IIIIO OII 2 Page:

screen with the report	3. Any feedback overall design? (If they offer a negative opinion, offer them positive
image)	feedback. For example, "how interesting what you say, we would like to know more about it")
	4. The report offers a snapshot at a certain moment. Would you find it useful to
	complete the survey periodically to follow up on those aspects that pose an
	opportunity for improvement? And, if so, how often would you consider it
	appropriate to carry out the evaluation? [The principal investigator recommends
	not addressing this point unless the participants speak about it spontaneously].
Conclusion:	Before closing, we would like to know if there is anything else that, in your opinion,
	we have not covered. Is there anything else about conducting this assessment and
	receiving the report that you would like us to know? Do you have any additional
	recommendations about something that you consider important?
Closing:	Thank you for participating and for spending your valuable time with us. We will work
	in coordination with you to offer you information about the analysis of the results of
	this project. If you have additional questions, you can contact Dr. Asya Agulnik
	directly or any of the EVAT team members at St. Jude who will always be happy to
	assist you.

Supplemental Table 2: Focus group code book

Domain	Code	Definition
	Ease of Interpretation	Comments on how easy or hard it is to interpret the report, including to use it to identify the center's strengths/weaknesses, both for the participant or members of their team
Interpreting Report	Report Interpretation	The participants actual interpretation of their report, including their center's strengths and weaknesses as described by the report (this shows us we need to work on x, or we do a good job with y), anything they were surprised by from their report and if they agree with it. General comments about ease of interpretation or how one could understand the strengths and weaknesses, without specific mentions of them, coded as "ease of interpretation".
	Report Use	Mentions of how the respondents or their team plans to use the report to improve their EVAT program or its sustainability
	Additional Information	Additional information that should be provided in the report to improve usability or anything that is missing that should be provided
	Written Material	Comments about the quality of the written text in the report and how it does/does not help with interpretation
	Second Page	Comments about the utility of the second page of the report
Report Components	Score Review Box	Comments about the score review box
	Domain Graph	Comments about the domain averages graphs
	Other individual components	Comments about an individual component of the report not mentioned in the other "report components' codes. General comments about the report should be coded as 'overall report'
Overall Look and Feel	Overall Report	Comments about the overall organization and design of the report, including things that should be adjusted or changed in the report in general, or things that are confusing. Do not code comments about individual components (code one of the 'report components')
CSAT	CSAT Components	Comments about clarity of specific CSAT domains or questions, including the Likert scale, not related to the report itself
CSAT	CSAT Use	Comments about how the CSAT was administered at the center (how many people, how often, etc.) or how it should be used in the future
Negative	Negative comment	Double code with any comment of something that is negative or needs improvement in the report or the CSAT tool itself

Supplemental Table 3: CSAT domains and time from PEWS implementation

		Indi	vidual-Lev	/el	С	enter-Leve	l
Domain	Time since Implementation of PEWS (Months)	n (%) n=169	Mean CSAT	p-value	n (%) n=29	Mean CSAT	p-value
	1-12 months	67 (39.6)	4.37		10 (34.5)	4.43	
Engaged Staff & Leadership	12-24 months	66 (39.1)	4.68	<0.001	13 (44.8)	4.66	0.040
	>24 months	36 (21.3)	4.64		6 (20.7)	4.65	
Engaged Stakeholders	1-12 months	67 (39.6)	4.13		10 (34.5)	4.18	
	12-24 months	66 (39.1)	4.50	<0.001	13 (44.8)	4.50	0.122
	>24 months	36 (21.3)	4.38		6 (20.7)	4.40	
Organizational Readiness	1-12 months	67 (39.6)	3.95		10 (34.5)	4.00	
	12-24 months	66 (39.1)	4.15	0.141	13 (44.8)	4.15	0.393
	>24 months	36 (21.3)	4.18		6 (20.7)	4.19	
	1-12 months	67 (39.6)	4.26		10 (34.5)	4.33	
Workflow Integration	12-24 months	66 (39.1)	4.61	<0.001	13 (44.8)	4.60	0.011
	>24 months	36 (21.3)	4.68		6 (20.7)	4.69	
	1-12 months	67 (39.6)	4.19		10 (34.5)	4.20	
Implementation & Training	12-24 months	66 (39.1)	4.47	0.004	13 (44.8)	4.41	0.224
	>24 months	36 (21.3)	4.51		6 (20.7)	4.51	
	1-12 months	67 (39.6)	4.36		10 (34.5)	4.40	
Monitoring & Evaluation	12-24 months	66 (39.1)	4.53	0.039	13 (44.8)	4.46	0.438
	>24 months	36 (21.3)	4.61		6 (20.7)	4.61	
	1-12 months	67 (39.6)	4.65		10 (34.5)	4.71	
Outcomes & Effectiveness	12-24 months	66 (39.1)	4.80	0.022	13 (44.8)	4.75	0.410
	>24 months	36 (21.3)	4.86		6 (20.7)	4.86	

Abbreviations: CSAT-Clinical Sustainability Assessment Tool, PEWS-Pediatric Early Warning System


Supplemental Table 4: Center demographics influencing CSAT results (among centers)

Category	Sub-Category	n (29)	mean	p-value
Hospital Characteris	-	_		
	General (adult and pediatric)	11	4.46	•
Type of Hospital	Oncology (adult and pediatric)	7	4.4	0.811
	Pediatric multidisciplinary	11	4.48	
	Public	21	4.49	0.245
Hospital Funding	Private or public/private partnership)	8	4.34	0.245
	1-75	12	4.44	
Annual New Cancer	76-150	9	4.47	0.96
Diagnoses	>150	8	4.46	
Pediatric Oncology	No pediatric oncology unit (integrated with pediatrics or other unit)	4	4.31	0.463
Structure	Separate pediatric	25	4.48	
Time since	1-12 months	10	4.32	
Implementation of	12-24 months	13	4.51	0.085
PEWS	>24 months	6	4.56	
Number of staff	0-249	5	4.41	0.74
working in center	>249	24	4.46	0.74


Abbreviations: CSAT-Clinical Sustainability Assessment Tool, PEWS-Pediatric Early Warning System

Supplemental Figure 4: CSAT result trends with time from PEWS implementation (center-level, n=29). Center-level scatter plot between time since implementation of PEWS (months) vs domain scores and

total CSAT result (using jitter method, added smooth line and correlation coefficient), demonstrating consistency of relationship between time since implementation and sustainability of PEWS.



Supplemental Figure 5: CSAT result trends with time from PEWS implementation (individual, n=169). Individual-level scatter plot between time since implementation of PEWS (months) vs domain scores and total CSAT result (using jitter method, added smooth line and correlation coefficient), demonstrating consistency of relationship between time since implementation and sustainability of PEWS.



Supplemental Table 5: Focus group participant demographics

Focus Group	Characteristics		n (%)
ICU Physicians	Total		8
	Gender	Male	4 (50%)
		Female	4 (50%)
	Countries Represented		6
Floor Physicians	Total		7
	Gender	Male	2 (29%)
		Female	5 (71%)
	Countries Represented		6
Nurses	Total		7
	Gender	Male	0 (0%)
		Female	7 (100%)
	Countries Represented		6
Overall	Total		22
	Gender	Male	6 (27%)
		Female	16 (72%)
	Countries Represented*		10

^{*}Counties Represented: Argentina, Chile, Dominican Republic, Ecuador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Peru

Abbreviations: ICU-Intensive Care Unit